

Wheat, Lawrence Joseph

EDUCATION:

Undergraduate: Indiana University, BA Medical Science, 1962 – 1966
Graduate: Indiana University Medical School, MD, 1966 – 1969
Postdoctoral: Indiana University Medical Center, Internship, 1969 -1970
Indiana University Medical Center, Residency, 1970 -1972
Indiana University Medical Center, Fellowship in
Infectious Diseases, 1972 - 1973 and 1975 - 1976

PROFESSIONAL APPOINTMENTS:

MiraVista Diagnostics, 2002-present, President and Director
MiraBella Technologies, 2002-present, President and Director

ACADEMIC APPOINTMENTS

Assistant Professor of Medicine, Infectious Diseases Division, Indiana University Medical Center, 1976 - 1980
Associate Professor of Medicine, Infectious Diseases Division, Indiana University Medical Center, 1980 - 1984
Professor of Medicine, Infectious Diseases Division, Indiana University Medical Center, 1984 – 2002.
Resigned to found MiraVista Diagnostics and MiraBella Technologies

HOSPITAL APPOINTMENTS:

Indiana University Medical Center, 1976 – 2002 [resigned to start MiraVista Diagnostics, LLC]
Indianapolis, Veterans' Administration Hospital, 1976 - 2002
Wishard Memorial Hospital, 1976 -2002

CONSULTANTSHIPS:

University of Texas, Southwestern Dallas TX

LICENSURE AND CERTIFICATION:

Indiana State Medical Board, 1969, #22902
Diplomate, American Board of Internal Medicine, 1972, Certificate #40920

PROFESSIONAL AFFILIATIONS:

American College of Physicians, Fellow
Infectious Disease Society of America, Fellow
Infectious Disease Society of Indiana
American Society of Microbiology
International Society for Human and Animal Mycology
Indiana State Medical Association
Marion County Medical Association
HIV Medicine Association of Infectious Disease Society of America
Medical Mycology Society of the Americas
European Society of Clinical Microbiology and Infectious Diseases
American College of Chest Physicians, #139508

EDITORIAL BOARDS:

Journal of Infectious Diseases, 2002-present
Current Fungal Infection Reports, 2007-

HONORS AND AWARDS:

Phi Eta Sigma, 1963
Alpha Omega Alpha, 1967
The Best Doctors in America, 1998
Indianapolis Business Journal Runner-up Healthcare Hero, 2001
Top Doctor, Indianapolis Monthly, 2001
Best Doctors, 2001-2002
Harry F. Dowling Award, 2004

FELLOWSHIP TRAINEES:

Zuhayr Tabarrah, M.D.
Boonmee Sathapatayavongs, M.D.
Frank Espersen, M.D.
Susan Kamel, Ph.D.
Susan Karimi, Ph.D.
Marvin Fojtasek, M.D.
Juan Torres, M.D.
Efiong Basse, D.V.M., Ph.D.
Satish Mocherla, M.D.
Samir Gupta, M.D.

VISITING PROFESSORSHIPS/INVITED LECTURES:

Lovelace Respiratory Research Institute, "Histoplasmosis and the immune response"
International Society for Human and Animal Mycology, Buenos Aires, Argentina, 2000-New Treatments
Endemic Mycoses, and Antigen and Molecular Diagnostics
National Medical Association, Washington, DC. Fungal Infections, 2000
Union Hospital, Terre Haute, IN, Histoplasmosis, 2001
Memorial Hospital of South Bend, South Bend, IN, An Update on Antifungals and HIV/AIDS, 2001
Advances in Treating Fungal Infections National Visiting Professor Program, Vanderbilt University, Nashville,
TN, Histoplasmosis, 2001
St. Mary's Medical Center, Evansville, IN, Systemic Fungal Infections, 2001
Anti-fungal Drug & Discovery, Princeton, NJ, 2001
Advances in Treating Fungal Infections, Histoplasmosis, Sloan-Kettering Cancer Center, New York, NY,
2001
Advances in Treating Fungal Infections, Histoplasmosis, University of Colorado, 2001
Current Treatment Strategies For Fungal Infections, University of Rochester Medical Center, 2001
Indiana University Family Practice Symposium, HIV Update, 2001
Fungal Diseases of the Lung, Ball Memorial Hospital, 2001
Endemic Mycoses, Madison County General Hospital, Jackson, TN, 2001
Treatment Updates for HIV, Reid Hospital, Richmond, IN 2001
Update on Fungal Infections, Akron City Hospital, Akron, OH 2001
Update on Fungal Infections, Medical Center, Columbus, GA, 2001
Update on Fungal Infections, Naval Medical Center, San Diego, CA, 2001
9th Annual HIV Update Conference, Indianapolis, IN, 2001
Anti-fungal Update, Aultman Medical Center, Canton, OH, 2002
Advances in Antifungal Therapy, Merck, Seattle, WA.
Shelbyville, IN Histoplasmosis Outbreak Update, Centers For Disease Control, Atlanta, GA, 2002
AIDS Update, Indiana Association of Osteopathic Physicians, 2002
Histoplasmosis, Regional Medical Center, Madisonville, KY 2002
Histoplasmosis, University of North Carolina, September 2002
Antifungal update, Indianapolis IN, September 2002
Histoplasmosis, Univ of Kansas, October 2002
Ambisome Visiting Faculty Program, Kansas City, KS, April 2003
Advances in Antifungal Therapy, Chicago, IL, March 2003
Ambisome Visiting Faculty Program, Madisonville, KY December 2002
Endemic Mycoses, Detroit, MI, April 2003
Infectious Diseases Grand Rounds, New York, NY, December 2003
Dowling Day, 2004, University of Illinois at Chicago, Chicago, Illinois
Fungal Pathogen Symposium. University of Wisconsin Medical School. Madison, WI, Sep 2004
Endemic Mycoses Grand Rounds, University of Wisconsin, Madison, WI, Sep 2004
Anti-Infectives Visiting Faculty Program, Charlottesville, VA
Infectious Disease Grand Rounds, New York Presbyterian Hospital, NY, Mar 2005
Noxafil National Advisory Board Meeting, St. Petersburg, FL, April 2005
Faculty of 1000 Medicine. Systemic Infections: Fungal Section Faculty Member. 2005
Dimorphic Fungal Pathogens, American Society of Microbiology, Denver, CO, March 2006
Ohio Infectious Disease Society, Fungal diagnostics, March 2007
University of Georgia, Augusta, Update on histoplasmosis; Fungal diagnostics, March 2007

PROFESSIONAL SERVICES:

AIDS Clinical Trials Group (ACTG), Executive Committee, Member, 1997-1999; 2001-2002
ACTG Scientific Agenda Steering Committee, Member, 1997-1999; 2001-2002

PROTOCOL CHAIR CLINICAL TRIALS

1. Itraconazole for Suppression of Relapse of Disseminated Histoplasmosis in Patients with the Acquired Immunodeficiency Syndrome. Sponsored by: AIDS Clinical Trials Group and National Institute of Allergy and Infectious Diseases, 1990.
2. Itraconazole for Primary Treatment and Suppression of Relapse of Disseminated Histoplasmosis in Patients with the Acquired Immunodeficiency Syndrome (AIDS). Sponsored by: AIDS Clinical Trials Group and National Institute of Allergy and Infectious Diseases, 1990.
3. Fluconazole for Induction Treatment and Suppression of Relapse of Disseminated Histoplasmosis in Patients the Acquired Immunodeficiency Syndrome (AIDS). Sponsored by: AIDS Clinical Trials Group and National Institute of Allergy and Infectious Diseases, 1991.
4. Itraconazole Prophylaxis Against Fungal Infections in Patients with Advanced Human Immunodeficiency Virus Infection: Randomized Placebo-Controlled Double-Blind Study. Sponsored by: National Institute of Allergy and Infectious Diseases and Mycoses Study Group, 1993.
5. Pharmacokinetics Study of I.V. Itraconazole Followed by Oral Dosing at 200 mg Twice Daily or 200 mg Once Daily in Patients with Advanced HIV Infection. Sponsored by: Janssen Research Foundation, 1995.
6. Safety and Efficacy of Ambisome with Conventional Amphotericin B for Induction Therapy of Histoplasmosis in Patients with AIDS. Sponsored by: National Institute of Allergy and Infectious Diseases and Mycoses Study Group, 1995.
7. Amphotericin B Oral Suspension for Fluconazole-Resistant Oral Candidiasis in HIV-Infected Patients. Sponsored by: AIDS Clinical Trials Group and National Institute of Allergy and Infectious Diseases, 1995.
8. A Multicenter, Case-Control Study of Risk Factors for Histoplasmosis in Patients with HIV. Sponsored by: Centers for Disease Control and Prevention and Mycoses Study Group, 1996.
9. Effect of High Intensity Antiretroviral Therapy on Viral Burden and Immune Function in the Lungs of HIV-Infected Subjects. Sponsored by: AIDS Clinical Trials Group and National Institute of Allergy and Infectious Diseases, 1997.
10. Discontinuation of Antifungal Therapy for Histoplasmosis Following Immunologic Response to Antiretroviral Therapy, 1998.

GRANTS AND CONTRACTS:

1. National Institutes of Health. AIDS Clinical Trials Unit 2U01AI25859. Principal Investigator, April 1992 – May 2002, Co-Investigator 1987-1991
2. Veterans' Administration Merit Review Program. Immunopathogenesis of Pulmonary Histoplasmosis. Principal Investigator, 1981-2002
3. Schering-Plough. Study of SCH in Murine Model of Histoplasmosis. Principal Investigator, 1995
4. Merck. Study of Merck Pneumocandin L-743-872 in a Murine Model of Histoplasmosis. 1995
5. Janssen. A Randomized Open Comparative Multicenter Study of Initial Treatment with Intravenous Itraconazole Versus Amphotericin B Followed by Consolidation Treatment with Itraconazole Capsules in Patients with Blastomycosis or Histoplasmosis. 1996
6. Shaman. Evaluation of Nikkomycin Z for Treatment of Histoplasmosis in a Murine Model. 1996
7. Eli Lilly Company. Evaluation of Lilly 303366 for Treatment of Histoplasmosis. 1996,
8. Eli Lilly Company. Lilly, LY303366 Dose-Ranging Efficacy and Safety Study in Oral Candidiasis. 1996
9. NexStar. A Compare the Safety and Efficacy of Ambisome with Conventional Amphotericin B for Induction Therapy of Histoplasmosis in Patients with AIDS. 1995
10. Janssen. Pharmacokinetics Study of I.V. Itraconazole Followed by Oral Dosing at 200 mg Twice Daily or 200 mg Once Daily in Patients with Advanced HIV Infection. 1995
11. The Centers for Disease Control and Prevention. A Multicenter, Case-Control Study of Risk Factors for Histoplasmosis in Patients with HIV. 1996
12. Immunex. A Phase III Randomized, Double-Blinded, Placebo Controlled Trial of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor (rhu GM-CSF) in Patients with Advanced HIV Disease. 1996
13. Schering-Plough. A Multicenter, Randomized, Double-Blind, Phase II Study to Evaluate the Safety, Tolerance and Efficacy of Multiple Doses of SCH 56592 vs. Fluconazole in the Treatment of Oropharyngeal Candidiasis in HIV-Positive Patients. 1997
14. Roche. A Randomized Phase IIIB Comparative Study To Evaluate Saquinavir TID vs BID
15. Aronex. Study of Aronex Nyotran for Efficacy against *Histoplasma capsulatum* in Culture, 1998

16. Gilead Sciences, A Phase II, Stratified, Randomized, Open-Label, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil and Indinavir in Combination with Zidovudine, Lamivudine or Stavudine for the Treatment Therapy Naïve HIV-Infected Patients with CD4 Counts, 1998
17. Schering-Plough, Open Label Non-Comparative Trial of SCH 56592 in the Treatment of Refractory Candidiasis in HIV-Infected Subjects, Principal Investigator, May 1998
18. Glaxo Wellcome, Continued Dual NRTI PI vs. Switch to Two NRTIs Plus Ziagen in HIV-1-Infected Adults with HIV-1 RNA < 50 copies/ml, Principal Investigator, 2000
19. Trimeris, Inc. tolerance and Pharmacokinetics (PK) of carbonate and Tris Buffer High Strength (100 mg/ml) Formulations of T20/Ro 29-9800 (HIV-1 Fusion Inhibitor) Compared to the Current Carbonate Formulation (50 mg/ml), each at doses of 75 to 100 mg, 2000
20. Triangle Pharmaceuticals, Inc, A Randomized, Open-Label Equivalence Study of FTC Versus Lamivudine in Patients on a Stable Triple Antiretroviral Therapy Regimen Containing Lamivudine, Stavudine or Zidovudine, and a Protease Inhibitor or Non-Nucleoside Reverse, 1999.
21. Gilead Sciences, Inc, A Phase 3, Randomized, Double Blind, Multicenter Study of the Treatment of Antiretroviral-, HIV-1 Infected Patients Comparing Tenofovir Disoproxil Fumarate Admin. In Combination with Lamivudine and Efavirenz Versus Stavudine, 2000.
22. Pfizer, Comparison of amphotericin B, itraconazole, fluconazole and amphotericin b plus fluconazole or itraconazole for treatment of cerebritis and meningitis in a murine model of histoplasmosis, 2000.
23. Chiron, A Phase III Multicenter Randomized Study of the Biological and Clinical Efficacy of Subcutaneous Recombinant, Human Interleukin-2 in HIV-infected Patients with Low CD4+ Counts Under Active Antiretroviral Therapy, 2000.
24. BioRad Laboratories, Evaluation of Platelia Aspergillus EIA in bronchoalveolar fluid, 2006
25. Basilia Pharma, Evaluation of the BAL 8557 in histoplasmosis, 2006
26. Schering-Plough, SCh 56592 posaconazole commercial assay development, 2006
27. Astellas Pharma US, Inc, Double-blind, randomized controlled trial voriconazole plus micafungin versus voriconazole plus placebo in the treatment of patients with proven or probable invasive aspergillosis, 2007. Provide central laboratory services for Platelia Aspergillus EIA testing.
28. NIH Clinical laboratory diagnosis for invasive aspergillosis. Co-investigator.

PATENTS

US patent application number 11/49,1647; fungal antigen immunoassay, filed July 24, 2006

NATIONAL/INTERNATIONAL MEETING PRESENTATIONS LAST 3 YEARS

2005

1. Detection of *Histoplasma capsulatum* in urine by PCR and its role in the diagnosis of histoplasmosis, YW Tang, HJ Lie, M. Durkin et al. American Society for Microbiology.
2. HIV modulates the dendritic cell response to *Histoplasma*. CA Hage, LL Kohli, P. Connolly et al. American Thoracic Society.
3. Comparison *Histoplasma* antigen EIA performed at MiraVista Diagnostics and Statens Serum Institute shows good correlation. MC Arendrup, LJ Wheat. European Congress of Clinical Microbiology and Infectious Diseases.
4. Activity of newer triazoles against fluconazole resistant *Histoplasma capsulatum*. LJ Wheat, P Connolly, M Smedema et al. Interscience Conference on Antimicrobial Agents and Chemotherapy.

2006

1. Improvement of the *Histoplasma* antigen immunoassay to allow for quantitation and reduction of interassay variability. LJ Wheat, EJ Hackett, PA Connolly. Dimorphic Fungal Infection Symposium, American Society for Microbiology.
2. Diagnosis of histoplasmosis and blastomycosis-what's new? LJ Wheat. Dimorphic Fungal Infection Symposium, American Society for Microbiology.
3. Improvements in diagnosis of histoplasmosis by antigen detection. LJ Wheat, P Connolly, M Durkin et al. Dimorphic Fungal Infection Symposium, American Society for Microbiology.
4. Diagnosis of coccidioidomycosis by antigen detection using cross reaction with *Histoplasma* antigen. LJ Wheat, T Kuberski, R Myers et al. International Coccidioidomycosis Symposium.
5. Cross-reactivity in the Platella *Aspergillus* galactomannan antigenemia assay caused by histoplasmosis. LJ Wheat., E Hackett, M. Durkin et al. Interscience Conference on Antimicrobial Agents and Chemotherapy.
6. Improved sensitivity and specificity of the second generation *Histoplasma* antigen detection assay: reduction in false-positive results caused by anti-rabbit antibodies. J Wheat, PA Connolly, M. Durkin et al. Interscience Conference on Antimicrobial Agents and Chemotherapy.

7. Improvement of the Histoplasma antigen immunoassay to allow for quantitation and reduction of interassay variability. LJ Wheat, EJ Hackett, PA Connolly. Interscience Conference on Antimicrobial Agents and Chemotherapy.
8. Diagnosis of coccidioidomycosis by antigen detection using cross reaction with *Histoplasma* antigen. LJ Wheat, T Kuberski, R Myers et al. Infectious Diseases Society of America.
9. Voriconazole use for endemic fungal infections. A Freifeld, L Prioia, D Andes et al. Infectious Diseases Society of America.
10. Persistent antigenuria during therapy for blastomycosis. R Bariola, M Durkin, LJ Wheat et al. Infectious Diseases Society of America.
11. Antigen testing for the diagnosis of blastomycosis. D Spector, J Wheat, D Bemis et al. American College of Veterinary Internal Medicine.
12. In vitro activity of a new triazole, BAL 8557, against *Histoplasma capsulatum* isolates from patients who failed fluconazole therapy. LJ Wheat, P Connolly, M Smedema et al. International Society for Human and Animal Mycology.
13. Outbreak of early disseminated histoplasmosis in solid organ transplant recipients: evidence of transmission from a common donor. R Pelletier, L Poirier, M Al-Mohri et al. International Society for Human and Animal Mycology.
14. Prospective assessment of the Platella Aspergillus EIA in bronchoalveolar lavage fluid for the early diagnosis of invasive aspergillosis in lung transplant recipients. H Shahid, DL Paterson, S Sean et al. World Transplant Congress.

2007

1. Correlation of quantitative antigen and culture in a murine model of histoplasmosis. CA Hage, K Knox, B Sullivan, et al. Focus on Fungal Infections.
2. evaluation of *Histoplasma capsulatum* antigen detection using the IMMY ALPHA *Histoplasma* antigen EIA. AM LeMonte, LL Egan, PA Connolly, MM Durkin, LJ Wheat, American Society for Microbiology General Meeting 2007

Reference List

1. Stewart A, Wheat LJ, and Madura J. Occurrence of pulmonary histoplasmosis after jejunioileal bypass for obesity. *Am Rev Respir Dis* 1978; 118:155.
2. Wheat J, Slama T, Eitzen H, Kohler R, Biesecker J, and French M. Unique features of the Indianapolis histoplasmosis outbreak. *Curr Chemother Infect Dis* 1979; 2:987-9.
3. French M, Eitzen H, Kohler R, Wheat J, Slama T, and Biesecker J. Serological studies in acute pulmonary histoplasmosis. *Curr Chemother Infect Dis* 1979; 2:985-7.
4. Kauffman CA, Slama TG, and Wheat LJ. Histoplasma capsulatum epididymitis. *J Urol* 1980; 125:434-5.
5. Ozols II and Wheat LJ. Erythema nodosum in an epidemic of histoplasmosis in Indianapolis. *Arch Dermatol* 1981; 117:709-12.
6. Wheat LJ, Slama TG, Eitzen HE, Kohler RB, French ML, and Biesecker JL. A large urban outbreak of histoplasmosis: clinical features. *Ann Intern Med* 1981; 94:331-7.
7. Wheat J, French ML, Kohler RB et al. The diagnostic laboratory tests for histoplasmosis: analysis of experience in a large urban outbreak. *Ann Intern Med* 1982; 97:680-5.
8. Wheat LJ, Slama TG, Eitzen HE, Kohler RB, French MLV, and Biesecker JL. A large urban outbreak of histoplasmosis: Clinical features. *Yearbook of Medicine* 1982;203-5.
9. Wheat LJ, Slama TG, Norton JA et al. Risk factors for disseminated or fatal histoplasmosis. Analysis of a large urban outbreak. *Ann Intern Med* 1982; 96:159-63.
10. Thornberry DK, Wheat LJ, Brandt KD, and Rosenthal J. Histoplasmosis presenting with joint pain and hilar adenopathy. "Pseudosarcoidosis". *Arthritis Rheum* 1982; 25:1396-402.
11. Wheat LJ, French MLV, Kohler RB et al. The diagnostic laboratory tests for histoplasmosis: Analysis of experience in a large urban outbreak. *Ann Intern Med* 1982; 97:680-5.
12. Wheat LJ, Kohler RB, French ML et al. Immunoglobulin M and G histoplasmal antibody response in histoplasmosis. *Am Rev Respir Dis* 1983; 128:65-70.
13. Wheat LJ, Stein L, Corya BC et al. Pericarditis as a manifestation of histoplasmosis during two large urban outbreaks. *Medicine (Baltimore)* 1983; 62:110-9.
14. Wheat LJ, Smith EJ, Sathapatayavongs B et al. Histoplasmosis in renal allograft recipients. Two large urban outbreaks. *Arch Intern Med* 1983; 143:703-7.
15. Sathapatayavongs B, Batteiger BE, Wheat J, Slama TG, and Wass JL. Clinical and laboratory features of disseminated histoplasmosis during two large urban outbreaks. *Medicine (Baltimore)* 1983; 62:263-70.
16. Rosenthal J, Brandt KD, Wheat LJ, and Slama TG. Rheumatologic manifestations of histoplasmosis in the recent Indianapolis epidemic. *Arthritis Rheum* 1983; 26:1065-70.
17. Schlech WF, III, Wheat LJ, Ho JL et al. Recurrent urban histoplasmosis, Indianapolis, Indiana, 1980-1981. *Am J Epidemiol* 1983; 118:301-12.
18. Weinberg GA, Kleiman MB, Grosfeld JL, Weber TR, and Wheat LJ. Unusual manifestations of histoplasmosis in childhood. *Pediatrics* 1983; 72:99-105.
19. Smith JW, Bartlett MS, and Wheat LJ. Culture proven histoplasmosis in immunocompromised patients. In: Easmon CSF and Gaya H eds. London: Academic Press, 1983:412-414.

20. Wheat LJ and French MLV. Diagnosis of histoplasmosis (response to letter by J.R. Lowell). *Ann Intern Med* 1983; 98:260.
21. Wheat LJ. Histoplasmosis: epidemiology, clinical manifestations, diagnosis, and therapy. *Med Grand Rounds* 1983; 2:364-74.
22. Wheat LJ. Serologic tests for histoplasmosis (in response). *Ann Intern Med* 1983; 98:560-1.
23. Wheat LJ and French MLV. The diagnostic approach in histoplasmosis. *Immunol Allergy Pract V* 1983; 9:19-28.
24. Payan DG, Wheat LJ, Brahmi Z et al. Changes in immunoregulatory lymphocyte populations in patients with histoplasmosis. *J Clin Immunol* 1984; 4:98-107.
25. Wheat LJ, Wass J, Norton J, Kohler RB, and French ML. Cavitory histoplasmosis occurring during two large urban outbreaks. Analysis of clinical, epidemiologic, roentgenographic, and laboratory features. *Medicine (Baltimore)* 1984; 63:201-9.
26. Wheat LJ and Small CB. Disseminated histoplasmosis in the acquired immune deficiency syndrome. *Arch Intern Med* 1984; 144:2147-9.
27. Kwon-Chung KJ, Bartlett MS, and Wheat LJ. Distribution of the two mating types among *Histoplasma capsulatum* isolates obtained from an urban histoplasmosis outbreak. *Sabouraudia* 1984; 22:155-7.
28. Starr JC, Hahn HH, and Wheat LJ. Farmer's lung serologies: An early manifestation of acute histoplasmosis. *Chest* 1984; 86:269-70.
29. Wheat LJ. Diagnosis and treatment of histoplasmosis. *Infect Dis Newslett* 1984; 3:19-26.
30. Wheat LJ and Bartlett M. *Histoplasma capsulatum* fungemia documented using the Dupont Isolator system. *Diagn Microbiol Infect Dis* 1984; 2:51-3.
31. Wheat LJ, Slama TG, and Zeckel ML. Histoplasmosis in the acquired immune deficiency syndrome. *Am J Med* 1985; 78:203-10.
32. Wheat J, French M, Batteiger B, and Kohler R. Cerebrospinal fluid *Histoplasma* antibodies in central nervous system histoplasmosis. *Arch Intern Med* 1985; 145:1237-40.
33. Brahmi Z, Wheat LJ, Rubin RH, and Schlaegel TF, Jr. Humoral and cellular immune response in ocular histoplasmosis. *Compr Ther* 1985; 11:24-30.
34. Wheat LJ. In reply: Ketoconazole therapy for AIDS patients with disseminated histoplasmosis. *Arch Intern Med* 1985; 145:2272.
35. Wheat J, French ML, Kamel S, and Tewari RP. Evaluation of cross-reactions in *Histoplasma capsulatum* serologic tests. *J Clin Microbiol* 1986; 23:493-9.
36. Wheat LJ, Kohler RB, and Tewari RP. Diagnosis of disseminated histoplasmosis by detection of *Histoplasma capsulatum* antigen in serum and urine specimens. *N Engl J Med* 1986; 314:83-8.
37. Wheat LJ, French MLV, Kamel S, and Tewari RP. Evaluation of cross-reactions in *Histoplasma capsulatum* serologic tests. *J Clin Microbiol* 1986; 23:493-9.
38. Wheat LJ. *Histoplasma capsulatum* serology (author's reply). *J Clin Microbiol* 1986; 23:905.
39. Coss KC, Wheat LJ, Conces DJ, Jr., Brashear RE, and Hull MT. Esophageal fistula complicating mediastinal histoplasmosis: Response to amphotericin B. *Am J Med* 1987; 83:343-6.

40. Wheat LJ, Rubin RH, Harris NL et al. Systemic salmonellosis in patients with disseminated histoplasmosis. *Arch Intern Med* 1987; 147:561-4.
41. Johnson J, Kabler JD, Gourley MF et al. Cave-associated histoplasmosis: Costa Rica. *MMWR* 1988; 37:312-3.
42. Wheat LJ. Histoplasmosis. *Infect Dis Clin North Am* 1988; 2:841-59.
43. Wheat LJ and Batteiger BE. Histoplasmosis. In: Vinken PJ, Bruyn GW, and Klawans HL eds. Amsterdam New York: Elsevier Science Publishers, 1988:437-443.
44. Wheat LJ, French ML, and Wass JL. Sarcoidlike manifestations of histoplasmosis. *Arch Intern Med* 1989; 149:2421-6.
45. Wheat LJ, Kohler RB, Tewari RP, Garten M, and French ML. Significance of *Histoplasma* antigen in the cerebrospinal fluid of patients with meningitis. *Arch Intern Med* 1989; 149:302-4.
46. Kamel SM, Wheat LJ, Garten M, Bartlett MS, Tansey MR, and Tewari RP. Production and characterization of murine monoclonal antibodies to *Histoplasma capsulatum* yeast cell antigens. *Infect Dis Clin North Am* 1989; 57:896-901.
47. Wheat LJ, Connolly-Stringfield P, Kohler RB, Frame PT, and Gupta MR. *Histoplasma capsulatum* polysaccharide antigen detection in diagnosis and management of disseminated histoplasmosis in patients with acquired immunodeficiency syndrome. *Am J Med* 1989; 87:396-400.
48. Tewari RP, Kohler RB, and Wheat LJ. Immune responses to subcellular antigens of *Histoplasma capsulatum*. In: Drouhet E, Cole GT, de Repentigny L, Latge JP, and Dupont B eds. Plenum Publishing Corporation, 1989:431-444.
49. Zimmerman SE, Connolly-Stringfield P, Wheat LJ, French MLV, and Kohler RB. Comparison of sandwich solid-phase radioimmunoassay and two enzyme-linked immunosorbent assays for detection of *Histoplasma capsulatum* polysaccharide antigen. *J Infect Dis* 1989; 160:678-85.
50. Wheat LJ. Diagnosis and management of histoplasmosis. *Eur J Clin Microbiol Infect Dis* 1989; 8:480-90.
51. Wheat LJ. Histoplasmosis: Method of. *Conn's Current Therapy* 1989;157-9.
52. Wheat LJ, Batteiger BE, and Sathapatayavongs B. *Histoplasma capsulatum* infections of the central nervous system. A clinical review. *Medicine (Baltimore)* 1990; 69:244-60.
53. Zimmerman SE, French MLV, Kleiman MB, and Wheat LJ. Evaluation of an enzyme-linked immunosorbent assay that uses ferrous metal beads for determination of antihistoplasmal immunoglobulins G and M. *J Clin Microbiol* 1990; 28:59-64.
54. Wheat LJ, Connolly-Stringfield PA, Baker RL et al. Disseminated histoplasmosis in the acquired immune deficiency syndrome: clinical findings, diagnosis and treatment, and review of the literature. *Medicine (Baltimore)* 1990; 69:361-74.
55. Raman C, Khardori N, von Behren LA, Wheat LJ, and Tewari RP. Evaluation of an ELISA for the detection of anti-*Histoplasma* ribosomal and antihistoplasmic antibodies in histoplasmosis. *J Clin Lab Anal* 1990; 4:199-207.
56. Williams BJ, Connolly-Stringfield P, Bartlett M et al. Correlation of *Histoplasma capsulatum* polysaccharide antigen with the severity of infection in murine histoplasmosis. *J Clin Lab Anal* 1991; 5:121-6.
57. Wheat LJ, Connolly-Stringfield P, Blair R, Connolly K, Garringer T, and Katz BP. Histoplasmosis relapse in patients with AIDS: detection using *Histoplasma capsulatum* variety *capsulatum* antigen levels. *Ann Intern Med* 1991; 115:936-41.

58. Mello KA, Wheat LJ, Lis R, Donnelly B, and Skolnik PR. Ketoconazole-responsive tonsillar infection due to Histoplasma capsulatum in an HIV-1-seropositive individual. *AIDS* 1991; 5:908-10.
59. Wheat LJ. Histoplasmosis in Indianapolis. *Clin Infect Dis* 1992; 14(suppl 1):S91-S99.
60. Witty LA, Steiner F, Curfman M, Webb D, and Wheat LJ. Disseminated histoplasmosis in patients receiving low-dose methotrexate therapy for psoriasis. *Arch Dermatol* 1992; 128:91-3.
61. Wheat LJ, Connolly-Stringfield P, Blair R et al. Effect of successful treatment with amphotericin B on Histoplasma capsulatum variety capsulatum polysaccharide antigen levels in patients with AIDS and histoplasmosis. *Am J Med* 1992; 92:153-60.
62. Wheat LJ, Connolly-Stringfield P, Williams B et al. Diagnosis of histoplasmosis in patients with the acquired immunodeficiency syndrome by detection of Histoplasma capsulatum polysaccharide antigen in bronchoalveolar lavage fluid. *Am Rev Respir Dis* 1992; 145:1421-4.
63. Buckley HR, Richardson MD, Evans EGV, and Wheat LJ. Immunodiagnosis of invasive fungal infection. *J Med Vet Mycol* 1992; 30,Suppl 1:249-60.
64. Dupont B, Graybill JR, Armstrong D, Laroche R, Touze JE, and Wheat LJ. Fungal infections in AIDS patients. *J Med Vet Mycol* 1992; 30,Suppl 1:19-28.
65. Wheat LJ. Histoplasmosis - Diagnosis and management. *Infect Dis Clin Pract* 1992; 1:287-90.
66. Wheat LJ. Histoplasmosis in AIDS. *AIDS Clin Care* 1992; 4:1-4.
67. Wheat LJ. Diagnosis and management of fungal infections in AIDS. *Curr Opin Infect Dis* 1993; 6:617-27.
68. Conces DJ, Jr., Stockberger SM, Tarver RD, and Wheat LJ. Disseminated histoplasmosis in AIDS: findings on chest radiographs. *AJR Am J Roentgenol* 1993; 160:15-9.
69. Fojtasek MF, Kamel S, Karimi S, Connolly-Stringfield P, and Wheat LJ. Monoclonal antibodies for detection of Histoplasma capsulatum variety capsulatum antigen in patients with histoplasmosis. *Serodiagn Immunother Infect Dis* 1993; 5:181-5.
70. Fojtasek MF, Sherman MR, Garringer T, Blair R, Wheat LJ, and Schnizlein-Bick CT. Local immunity in lung-associated lymph nodes in a murine model of pulmonary histoplasmosis. *Infect Immun* 1993; 61:4607-14.
71. Wheat J, Hafner R, Wulfsohn M et al. Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome. The National Institute of Allergy and Infectious Diseases Clinical Trials and Mycoses Study Group Collaborators. *Ann Intern Med* 1993; 118:610-6.
72. Wheat J. Diagnosis of histoplasmosis-review of current methods. In: Bossche HV ed. New York: Plenum Press, 1993:333-340.
73. Wheat LJ. The role of the serologic diagnostic laboratory and the diagnosis of fungal disease. In: Sarosi GA and Davies SF eds. 2. New York: RavenPress, 1993:29-38.
74. Norris S, Wheat J, McKinsey D et al. Prevention of relapse of histoplasmosis with fluconazole in patients with the acquired immunodeficiency syndrome. *Am J Med* 1994; 96:504-8.
75. Wheat J. Histoplasmosis: recognition and treatment. *Clin Infect Dis* 1994; 19 Suppl 1:S19-S27.
76. Fojtasek MF, Kleiman MB, Connolly-Stringfield P, Blair R, and Wheat LJ. The Histoplasma capsulatum antigen assay in disseminated histoplasmosis in children. *Pediatr Infect Dis J* 1994; 13:801-5.

77. Kohler S, Blair R, Schnizlein-Bick C, Fojtasek M, Connolly-Stringfield P, and Wheat J. Clearance of *Histoplasma capsulatum* variety *capsulatum* antigen is useful for monitoring treatment of experimental histoplasmosis. *J Clin Lab Anal* 1994; 8:1-3.
78. Williams B, Fojtasek M, Connolly-Stringfield P, and Wheat J. Diagnosis of histoplasmosis by antigen detection during an outbreak in Indianapolis, Ind. *Arch Pathol Lab Med* 1994; 118:1205-8.
79. Wheat J. Fungal infections in the immunocompromised host. In: Woolford S ed. 3. New York: Plenum Publishing, 1994.
80. Wheat, L. J. Observation. 1994.
Ref Type: Unpublished Work
81. Wheat LJ and Goldman M. Antifungal prophylaxis in AIDS: Should it be the standard of care? *AIDS Clin Care* 1994; 6:27-30.
82. McMahon JP, Wheat J, Sobel ME, Pasula R, Downing JF, and Martin WJ, II. Murine laminin binds to *Histoplasma capsulatum*. A possible mechanism of dissemination. *J Clin Invest* 1995; 96:1010-7.
83. Savides TJ, Gress FG, Wheat LJ, Ikenberry S, and Hawes RH. Dysphagia due to mediastinal granulomas: Diagnosis with endoscopic ultrasonography. *Gastroenterology* 1995; 109:366-73.
84. Wheat J, Hafner R, Korzun AH et al. Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trial Group. *Am J Med* 1995; 98:336-42.
85. Wheat J. Endemic mycoses in AIDS: a clinical review. *Clin Microbiol Rev* 1995; 8:146-59.
86. Sarosi GA, Ampel NM, Cohn DL et al. ATS Guidelines: Fungal Infections in HIV-Infected Persons-I. *Am J Respir Crit Care Med* 1995;816.
87. Wheat L. Newer therapy for histoplasmosis. *JAAPA* 1996;96.
88. Wheat L. Histoplasmosis in the Acquired Immunodeficiency Syndrome. *Current Topics in Medical Mycology* 1996; 7:7-18.
89. Wheat J. Histoplasmosis in the acquired immunodeficiency syndrome. *Curr Top Med Mycol* 1996; 7:7-18.
90. Wheat LJ. Histoplasmosis Susceptibility in Humans. In: Jacobs PH and Nall L eds. Vol 12. New York: Marcel Dekker, Inc., 1996:237-251.
91. Wheat L. Candidiasis, histoplasmosis, aspergillosis, and miscellaneous mycoses and AIDS. In: Crowe S, Hoy J, and Mills J eds. New York: Cambridge Univ. Press, 1996:340-355.
92. Wheat J. Histoplasmosis. Experience during outbreaks in Indianapolis and review of the literature. *Medicine (Baltimore)* 1997; 76:339-54.
93. Wheat J, Wheat H, Connolly P et al. Cross-reactivity in *Histoplasma capsulatum* variety *capsulatum* antigen assays of urine samples from patients with endemic mycoses. *Clin Infect Dis* 1997; 24:1169-71.
94. Durkin MM, Connolly PA, and Wheat LJ. Comparison of radioimmunoassay and enzyme-linked immunoassay methods for detection of *Histoplasma capsulatum* var. *capsulatum* antigen. *J Clin Microbiol* 1997; 35:2252-5.
95. Wheat J, Marichal P, Vanden Bossche H, Le Monte A, and Connolly P. Hypothesis on the mechanism of resistance to fluconazole in *Histoplasma capsulatum*. *Antimicrob Agents Chemother* 1997; 41:410-4.

96. Wheat J, MaWhinney S, Hafner R et al. Treatment of histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Acquired Immunodeficiency Syndrome Clinical Trials Group and Mycoses Study Group. *Am J Med* 1997; 103:223-32.
97. Hecht FM, Wheat J, Korzun AH et al. Itraconazole maintenance treatment for histoplasmosis in AIDS: a prospective, multicenter trial. *J Acquir Immune Defic Syndr Hum Retrovirol* 1997; 16:100-7.
98. Goldman M and Wheat LJ. Cryptococcal Infections. In: Fishman AP, Elias JA, Fishman JA, Grippi MA, Kaiser LR, and Senior RM eds. 3. Vol 2. R.R. Donnelley & Sons Company, 1997:2305-2312.
99. Goldman M and Wheat LJ. Update on the treatment and prevention of candidiasis in immunocompromised patients. *Issues in Mycology* 1997; 2:2-20.
100. Wheat J. Histoplasmosis: Experience during outbreaks in Indianapolis and review of the literature. *Medicine (Baltimore)* 1997; 76:339-54.
101. Wheat LJ. Endemic Mycoses of North America: Histoplasmosis, Coccidioidomycosis, and Blastomycosis. In: Fishman AP, Elias JA, Fishman JA, Grippi MA, Kaiser LR, and Senior RS eds. 3. Vol 2. McGraw and Hill, 1997:2289-2303.
102. Zingman B, Zackin R, Wheat J et al. Amphotericin B oral suspension for fluconazole-resistant oral candidates in HIV infected patients. 1997:271.
103. Brooks JT and Wheat LJ. Histoplasmosis: Update 1998. *AIDS Clin Care* 1998; 10:4-5.
104. Graybill JR, Vazquez J, Darouiche RO et al. Randomized trial of itraconazole oral solution for oropharyngeal candidiasis in HIV/AIDS patients. *Am J Med* 1998; 104:33-9.
105. Wheat LJ. *Histoplasma capsulatum* Antigen Detection: Comparison of the Performance Characteristics of New Inhibition Immunoassay to Those of an Established Antibody Sandwich Immunoassay (**author's reply**). *J Clin Microbiol* 1999; 37:2387.
106. Connolly P, Wheat J, Schnizlein-Bick C et al. Comparison of a new triazole antifungal agent, Schering 56592, with itraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice. *Antimicrob Agents Chemother* 1999; 43:322-8.
107. Wheat, Joe, Gomez B et al. *Histoplasma capsulatum* Antigen Detection: Comparison of the Performance Characteristics of a New Inhibition Immunoassay to Those of an Established Antibody Sandwich Immunoassay. *J Clin Microbiol* 1999; 37:2387.
108. McKinsey DS, Wheat LJ, Cloud GA et al. Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: randomized, placebo-controlled, double-blind study. National Institute of Allergy and Infectious Diseases Mycoses Study Group. *Clin Infect Dis* 1999; 28:1049-56.
109. Wheat J. *Histoplasma capsulatum* antigen detection: comparison of the performance characteristics of a new inhibition immunoassay to those of an established antibody sandwich immunoassay. *J Clin Microbiol* 1999; 37:2387.
110. Jiang B, Bartlett MS, Allen SD et al. Typing of *Histoplasma capsulatum* isolates based on nucleotide sequence variation in the internal transcribed spacer regions of rRNA genes. *J Clin Microbiol* 2000; 38:241-5.
111. Goldberg J, Connolly P, Schnizlein-Bick C et al. Comparison of nikkomycin Z with amphotericin B and itraconazole for treatment of histoplasmosis in a murine model. *Antimicrob Agents Chemother* 2000; 44:1624-9.

112. Kohler S, Wheat LJ, Connolly P et al. Comparison of the echinocandin caspofungin with amphotericin B for treatment of histoplasmosis following pulmonary challenge in a murine model. *Antimicrob Agents Chemother* 2000; 44:1850-4.
113. LeMonte AM, Washum KE, Smedema ML, Schnizlein-Bick C, Kohler SM, and Wheat LJ. Amphotericin B combined with itraconazole or fluconazole for treatment of histoplasmosis. *J Infect Dis* 2000; 182:545-50.
114. Garringer TO, Wheat LJ, and Brizendine EJ. Comparison of an established antibody sandwich method with an inhibition method of *Histoplasma capsulatum* antigen detection. *J Clin Microbiol* 2000; 38:2909-13.
115. Limaye AP, Connolly PA, Sagar M et al. Transmission of *Histoplasma capsulatum* by organ transplantation. *N Engl J Med* 2000; 343:1163-6.
116. Wheat LJ, Chetchotisakd P, Williams B, Connolly P, Shutt K, and Hajjeh R. Factors associated with severe manifestations of histoplasmosis in AIDS. *Clin Infect Dis* 2000; 30:877-81.
117. Zhou H, Goldman M, Wu J et al. A pharmacokinetic study of intravenous itraconazole followed by oral administration of itraconazole capsules in patients with advanced human immunodeficiency virus infection. *J Clin Pharmacol* 1998; 38:593-602.
118. Goldman M, Cloud GA, Smedema M et al. Does long-term itraconazole prophylaxis result in in vitro azole resistance in mucosal *Candida albicans* isolates from persons with advanced human immunodeficiency virus infection? *Antimicrob Agents Chemother* 2000; 44:1585-7.
119. Wheat J, Sarosi G, McKinsey D et al. Practice guidelines for the management of patients with histoplasmosis. *Infectious Diseases Society of America. Clin Infect Dis* 2000; 30:688-95.
120. Connolly P, Wheat LJ, Schnizlein-Bick C et al. Comparison of a new triazole, posaconazole, with itraconazole and amphotericin B for treatment of histoplasmosis following pulmonary challenge in immunocompromised mice. *Antimicrob Agents Chemother* 2000; 44:2604-8.
121. Basgoz N and Mattia AR. A 38-year old man with AIDS and the recent onset of diarrhea, hematochezia, fever, and pulmonary infiltrates. *N Engl J Med* 1994; 330:273-80.
122. Hage CA, Goldman M, and Wheat LJ. Mucosal and invasive fungal infections in HIV/AIDS. *Eur J Med Res* 2000; 7:236-41.
123. Torres J, Goldman M, Wheat LJ et al. Diagnosis of *Pneumocystis carinii* pneumonia in human immunodeficiency virus-infected patients with polymerase chain reaction: a blinded comparison to standard methods. *Clin Infect Dis* 2000; 30:141-5.
124. Hajjeh RA, Pappas PG, Henderson H et al. Multicenter case-control study of risk factors for histoplasmosis in human immunodeficiency virus-infected persons. *Clin Infect Dis* 2001; 32:1215-20.
125. Ciulla TA, Piper HC, Xiao M, and Wheat LJ. Presumed ocular histoplasmosis syndrome: update on epidemiology, pathogenesis, and photodynamic, antiangiogenic, and surgical therapies. *Curr Opin Ophthalmol* 2001; 12:442-9.
126. Wheat LJ, Cloud G, Johnson PC et al. Clearance of fungal burden during treatment of disseminated histoplasmosis with liposomal amphotericin B versus itraconazole. *Antimicrob Agents Chemother* 2001; 45:2354-7.
127. Durkin M, Kohler S, Schnizlein-Bick C et al. Chronic infection and reactivation in a pulmonary challenge model of histoplasmosis. *J Infect Dis* 2001; 183:1822-4.
128. Wheat LJ. Laboratory diagnosis of histoplasmosis: update 2000. *Semin Respir Infect* 2001; 16:131-40.

129. Wheat LJ, Connolly P, Smedema M, Brizendine E, and Hafner R. Emergence of resistance to fluconazole as a cause of failure during treatment of histoplasmosis in patients with acquired immunodeficiency disease syndrome. *Clin Infect Dis* 2001; 33:1910-3.
130. Le Monte AM, Goldman M, Smedema ML et al. DNA fingerprinting of serial *Candida albicans* isolates obtained during itraconazole prophylaxis in patients with AIDS. *Med Mycol* 2001; 39:207-13.
131. Finquelievich JL, Odds FC, Telles FQ, and Wheat LJ. New advances in antifungal treatment. *Medical Mycology* 2001; 38:317-22.
132. Mocherla S and Wheat LJ. Treatment of histoplasmosis. *Sem Resp Infect* 2001; 16:141-8.
133. Karimi K, Wheat LJ, Connolly P et al. Differences in histoplasmosis in patients with acquired immunodeficiency syndrome in the United States and Brazil. *J Infect Dis* 2002; 186:1655-60.
134. Wheat LJ, Garringer T, Brizendine E, and Connolly P. Diagnosis of histoplasmosis by antigen detection based upon experience at the histoplasmosis reference laboratory. *Diagn Microbiol Infect Dis* 2002; 43:29-37.
135. Buxton JA, Dawar M, Wheat LJ et al. Outbreak of histoplasmosis in a school party that visited a cave in Belize: role of antigen testing in diagnosis. *J Travel Med* 2002; 9:48-50.
136. Vail GM, Young RS, Wheat LJ, Filo RS, Cornetta K, and Goldman M. Incidence of histoplasmosis following allogeneic bone marrow transplant or solid organ transplant in a hyperendemic area. *Transpl Infect Dis* 2002; 4:148-51.
137. Vail GM, Mocherla S, Wheat LJ et al. Cellular immune response in HIV-infected patients with histoplasmosis. *J Acquir Immune Defic Syndr* 2002; 29:49-53.
138. Wheat LJ, Connolly P, Haddad N, Le Monte A, Brizendine E, and Hafner R. Antigen clearance during treatment of disseminated histoplasmosis with itraconazole versus fluconazole in patients with AIDS. *Antimicrob Agents Chemother* 2002; 46:248-50.
139. Johnson PC, Wheat LJ, Cloud GA et al. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. *Ann Intern Med* 2002; 137:105-9.
140. Haynes RR, Connolly PA, Durkin MM et al. Antifungal therapy for central nervous system histoplasmosis, using a newly developed intracranial model of infection. *J Infect Dis* 2002; 185:1830-2.
141. Wheat LJ, Goldman M, and Sarosi G. State-of-the-art review of pulmonary fungal infections. *Semin Respir Infect* 2002; 17:158-81.
142. Hage CA, Goldman M, and Wheat LJ. Mucosal and invasive fungal infections in HIV/AIDS. *Eur J Med Res* 2002; 7:236-41.
143. Wheat LJ, Durkin M, Schnizlein-Bick C et al. Effect of CD40 ligand on the course of murine histoplasmosis. *Med Mycol* 2002; 40:501-5.
144. Wheat LJ. Editorial Comment: Diagnosis of Histoplasmosis in AIDS. *The AIDS Reader* 2002; 12:320.
145. Mathew G, Smedema M, Wheat LJ, and Goldman M. Relapse of coccidioidomycosis despite immune reconstitution after fluconazole secondary prophylaxis in a patient with AIDS. *Mycoses* 2003; 46:42-4.
146. Wood KL, Hage CA, Knox KS et al. Histoplasmosis after Treatment with Anti-TNF- α Therapy. *Am J Respir Crit Care Med* 2003; 167:1279-82.

147. Wheat LJ and Kauffman CA. Histoplasmosis. *Infect Dis Clin North Am* 2003; 17:1-19, vii.
148. Wheat LJ. Current diagnosis of histoplasmosis. *Trends Microbiol* 2003; 11:488-94.
149. Schnitzlein-Bick C, Durkin M, Kohler S et al. Effects of CD4 and CD8 T lymphocyte depletion on the course of histoplasmosis following pulmonary challenge. *Med Mycol* 2003; 41:189-97.
150. Wheat L. Rapid diagnosis of invasive aspergillosis by antigen detection. *Transpl Infect Dis* 2003; 5:158-66.
151. Wheat LJ. Combination therapy for aspergillosis: is it needed, and which combination? *J Infect Dis* 2003; 187:1831-3.
152. Wheat LJ, Connolly P, Durkin M et al. False-positive *Histoplasma* antigenemia caused by antithymocyte globulin antibodies. *Transpl Infect Dis* 2004; 6:23-7.
153. Durkin M, Witt J, LeMonte A, Wheat B, and Connolly P. Antigen assay with the potential to aid in diagnosis of blastomycosis. *J Clin Microbiol* 2004; 42:4873-5.
154. Wheat LJ, Conces DJ, Jr., Allen S, Blue-Hnidy D, and Loyd J. Pulmonary Histoplasmosis Syndromes: Recognition, Diagnosis, and Management. *Seminars in Respiratory and Critical Care Medicine* 2004; 25:129-44.
155. Chamany S, Mirza SA, Fleming JW et al. A large histoplasmosis outbreak among high school students in Indiana, 2001. *Pediatr Infect Dis J* 2004; 23:909-14.
156. Durkin MM, Connolly PA, Karimi K et al. Pathogenic Differences between North American and Latin American Strains of *Histoplasma capsulatum* var. *capsulatum* in Experimentally Infected Mice. *J Clin Microbiol* 2004; 42:4370-3.
157. Goldman M, Zackin R, Fichtenbaum CJ et al. Safety of discontinuation of maintenance therapy for disseminated histoplasmosis after immunologic response to antiretroviral therapy. *Clin Infect Dis* 2004; 38:1485-9.
158. Wheat and L. Joseph. Therapy for Severe Histoplasmosis: What's Best? *Clin Infect Dis* 2004; 38:463.
159. Kahi CJ, Wheat LJ, Allen SD, and Sarosi GA. Gastrointestinal histoplasmosis. *Am J Gastroenterol* 2005; 100:220-31.
160. Goldman M, Cloud GA, Wade KD et al. A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40. *Clin Infect Dis* 2005; 41:1473-80.
161. Hage CA, Wheat LJ, Twigg HL, and Knox KS. Infliximab does not affect dendritic cells' mediated lymphoproliferative response to *Histoplasma capsulatum*. *Clin Infect Dis* 2005; 41:1685-7.
162. Wheat LJ, Musial CE, and Jenny-Avital E. Diagnosis and management of central nervous system histoplasmosis. *Clin Infect Dis* 2005; 40:844-52.
163. Wheat LJ. Galactomannan Antigenemia Detection for Diagnosis of Invasive Aspergillosis, Part I. *Clinical Microbiology Newsletter* 2005; 27:51-7.
164. Wheat LJ. Galactomannan Antigenemia Detection for Diagnosis of Invasive Aspergillosis, Part II. *Clinical Microbiology Newsletter* 2005; 27:59-63.
165. Wheat LJ. Histoplasmosis: a review for clinicians from non-endemic areas. *Mycoses* 2006; 49:274-82.

166. Wheat LJ, Connolly P, Smedema M et al. Activity of newer triazoles against *Histoplasma capsulatum* from patients with AIDS who failed fluconazole. *J Antimicrob Chemother* 2006; 57:1235-9.
167. Tang YW, Li H, Durkin MM et al. Urine polymerase chain reaction is not as sensitive as urine antigen for the diagnosis of disseminated histoplasmosis. *Diagn Microbiol Infect Dis* 2006.
168. Wheat LJ. Antigen detection, serology, and molecular diagnosis of invasive mycoses in the immunocompromised host. *Transpl Infect Dis* 2006; 8:128-39.
169. Wheat LJ. Improvements in diagnosis of histoplasmosis. *Expert Opin Biol Ther* 2006; 6:1207-21.
170. Wheat LJ, Connolly P, Durkin M, Book BK, and Pescovitz MD. Elimination of false-positive *Histoplasma* antigenemia caused by human anti-rabbit antibodies in the second-generation *Histoplasma* antigen assay. *Transpl Infect Dis* 2006; 8:219-21.
171. Mongkolrattanothai K, Peev M, Wheat LJ, and Marcinak J. Urine antigen detection of blastomycosis in pediatric patients. *Pediatr Infect Dis J* 2006; 25:1076-8.
172. Wheat LJ, Hackett E, Durkin M et al. Histoplasmosis-Associated Cross-Reactivity in the BioRad Platelia Aspergillus Enzyme Immunoassay. *Clin Vaccine Immunol* 2007; 14:638-40.
173. Kuberski T, Myers R, Wheat LJ, Kubak BM, Bruckner D, and Peuges D. Diagnosis of coccidioidomycosis by antigen detection using cross-reaction with a *Histoplasma* antigen. *Clinical Infect Diseases* 2007; 44:e50-e54.
174. Hage CA, Reynolds JM, Durkin M, Wheat LJ, and Knox KS. Plasmalyte as a cause of false-positive results for *Aspergillus galactomannan* in bronchoalveolar lavage fluid. *J Clin Microbiol* 2007; 45:676-7.
175. Wheat LJ, Witt J, III, Durkin M, and Connolly P. Reduction in false antigenemia in the second generation *Histoplasma* antigen assay. *Med Mycol* 2007; 45:169-71.
176. Hage CA, Davis TE, Egan L et al. Diagnosis of pulmonary histoplasmosis and blastomycosis by detection of antigen in bronchoalveolar lavage fluid using an improved second-generation enzyme-linked immunoassay. *Respir Med* 2007; 101:43-7.
177. Clancy CJ, Jaber RA, Leather HL et al. Bronchoalveolar lavage galactomannan in the diagnosis of invasive pulmonary aspergillosis among solid organ transplant recipients. *J Clin Microbiol* 2007.
178. De Jesus M, Hackett E, Durkin M et al. Galactoxylomannan Does Not Exhibit Cross-Reactivity in the Platelia Aspergillus Enzyme Immunoassay. *Clin Vaccine Immunol* 2007; 14:624-7.
179. Wheat L.J. Fungal antigen immunoassay. 20070020711. 2007. United States. 7-24-2006.
Ref Type: Patent
180. Freifeld A, Arnold S, Ooi W et al. Relationship of Blood Level and Susceptibility in Voriconazole Treatment of Histoplasmosis. *Antimicrob Agents Chemother* 2007; 51:2656-7.
181. Husain S, Paterson DL, Studer SM et al. Aspergillus Galactomannan Antigen in the Bronchoalveolar Lavage Fluid for the Diagnosis of Invasive Aspergillosis in Lung Transplant Recipients. *Transplantation* 2007; 83:1330-6.
182. Kleiman MB, Wheat LJ, and Bowyer S. Histoplasmosis in a child with JRA on low-dose methotrexate. *Rheumatology (Oxford)* 2007; 46:1215-6.
183. LeMonte A, Egan L, Connolly P, Durkin M, and Wheat LJ. Evaluation of the IMMY ALPHA *Histoplasma* Antigen Enzyme Immunoassay for Diagnosis of Histoplasmosis Marked by Antigenuria. *Clin Vaccine Immunol* 2007; 14:802-3.

184. Tarr M, Marcinak J, Mongkolrattanothai K et al. Blastomyces antigen detection for monitoring progression of blastomycosis in a pregnant adolescent. *Infect Dis Obstet Gynecol* 2007; 2007:89059.

CHAPTERS [since 1998]:

1. Wheat LJ: Endemic mycoses of North America: histoplasmosis, coccidioidomycosis, and blastomycosis. In: Fishman's Pulmonary Diseases and Disorders, edited by AP Fishman, JA Elias, JA Fishman, MA Grippi, LR Kaiser, and RS Senior. RR Donnelley & Sons Co., vol. 2, 3rd edition, ch. 148, 2289-2303, 1998.
2. Goldman M, and LJ Wheat: Cryptococcal infections. In: Fishman's Pulmonary Diseases and Disorders, edited by AP Fishman, JA Elias, JA Fishman, MA Grippi, LR Kaiser, and RS Senior. RR Donnelley & Sons Co., vol 2, 3rd edition, ch. 149, 2305-2312, 1998.
3. Tewari RP, Wheat LJ, Ajello L: Agents of histoplasmosis. In: Topley & Wilson's Microbiology and Microbial Infections, edited by L Collier, A Balows and M Sussman. Oxford University Press, Inc. 9th ed., vol. 4, cha. 20, 373-394, 1998.
4. Wheat LJ, Goldman M: Histoplasmosis and other endemic mycoses, aspergillosis and rare mycoses. In: Management of the HIV Infected Patient, ed. Crowe, Hoy, Mills, pub. Cambridge University Press, 2nd ed., 2000 (in press).
5. Wheat J: Histoplasmosis. In: AIDS Therapy, ed. R. Dolin, H. Masur, M.S. Saag, pub. WB Saunders Co. 1999, ch. 33:412-422.
6. Wheat LJ: Histoplasmosis. In: Atlas of Infectious Diseases, Ed. Richard Diamond. 1998. Publisher Current Medicine, Inc.
7. Wheat LJ: Serologic Diagnosis of Fungal Disease. In: Fungal Diseases of the Lung. ed. G. Sarosi, S. Davies, pub. Lippincott Williams & Wilkins, 2000.
8. Wheat LJ: Histoplasmosis. In: Fungal Diseases of the Lung. ed. G. Sarosi, S. Davies, pub. Lippincott Williams & Wilkins, 2000.
9. Wheat LJ: Endemic mycoses. In: Cohen and Powderly: Infectious Diseases, 2002.
10. Wheat LJ: Sarosi G; Goldman M: Fungal Disease in the Immunocompromised Host. In Rubin Infections in the Immunocompromised Host, 2002
11. Wheat LJ: Histoplasmosis, in Antimicrobial Chemotherapy, ed. Victor L. Yu, Williams and Wilkins publisher, 2002
12. Wheat LJ: Histoplasmosis, in Infectious Diseases-3; Ed. J Bartlett, S. Gorbach. Publisher Lippincott Williams & Wilkins, 2002
13. Wheat LJ: Histoplasmosis, in Expert Guide to Infectious Diseases; Ed. JS Tan, Publisher American College of Physicians, 2002
14. Wheat Joe: Histoplasma. In: Infectious Diseases, Third Edition. Publisher Lippincott, Williams and Wilkins. 2004.
15. Wheat L. Joseph, M.D. Histoplasmosis. In: Conn's Current Therapy, 2004. Publisher Elsevier 2004.
16. L. Joseph Wheat. Systemic mycoses in the immunocompromised host. In: Immunomodulators as Promising Therapeutic Agents Against Infectious Disease, 2004. Research Signpost, 2004.